rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
|
25359494 |
2015 |
rs121913530
|
|
|
0.040 |
GeneticVariation |
BEFREE |
KRAS exon 2 analysis was performed on 2239 CRC and 2.2% harbored the c.34G>T transversion.
|
26056087 |
2015 |
rs61764370
|
|
|
0.030 |
GeneticVariation |
BEFREE |
A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC.
|
26162609 |
2015 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our finding that KRAS codon 13 mutations (in particular G13D) are associated with inferior survival in BRAF wild-type CRCs in Chinese patients was not reported thus far.
|
25367198 |
2014 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We have investigated Ca(2+) signalling in two human colorectal cancer cell lines and their isogenic derivatives in which the allele encoding oncogenic K-Ras (G13D) was deleted by homologous recombination.
|
24522186 |
2014 |
rs61764370
|
|
|
0.030 |
GeneticVariation |
BEFREE |
A PubMed search was conducted to identify all studies reporting on KRAS let-7 microRNA-binding site polymorphism (LCS6; rs61764370) and colorectal cancer outcome.
|
24890702 |
2014 |
rs712
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Stratified analyses revealed that CRC patients with the let-7 KRAS rs712 TT genotype were more likely to have clinical stage III or IV disease (OR = 3.29, 95% CI, 1.32-8.20) and distant metastasis (OR = 4.70, 95% CI, 1.81-12.25).
|
23975373 |
2014 |
rs397517040
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We detected a GGT insertion between codons 12 and 13 (c.36_37insGGT;p.G12_G13insG) in a CRC patient.
|
24594115 |
2014 |
rs121913238
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.
|
23400451 |
2013 |
rs121913529
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In contrast, in KRAS-mutant CRC cells (DLD-1(G13D) and SW480(G12V)), KRAS knocked-down by KRAS-siRNA led to ERCC1 upregulation and increased oxaliplatin resistance.
|
23209813 |
2012 |
rs121913529
|
|
|
0.800 |
GeneticVariation |
BEFREE |
KRAS codon 12 mutations (in particular, c.35G>T), but not codon 13 mutations, are associated with inferior survival in BRAF wild-type colorectal cancer.
|
22753589 |
2012 |
rs121913529
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The aim of our study was to evaluate the combined effects of MSI, BRAF(V600E) and specific KRAS mutation (Gly → Asp; G12D, Gly → Asp, G13D; Gly → Val; G12V) on prognosis in 404 sporadic and 94 hereditary CRC patients.
|
20162668 |
2010 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We aimed to study proliferation and survival effects induced by BRAF inhibition in MSI CRC cell lines harbouring distinct genetic backgrounds (BRAF V600E or KRAS G13D).
|
18098337 |
2008 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, HNPCC CRCs had more G13D mutations than MSS (P < 0.0001), MSI-H (P = 0.02) or MSI-H tumours with hMLH1 hypermethylation (P = 0.03).
|
15294875 |
2004 |
rs121913529
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Recent evidence associates the codon 12 valine-for-glycine (G12V) mutant Ki-Ras protein with higher stage and increased lethality of colorectal carcinomas, while the codon 12 aspartate-for-glycine (G12D) Ras mutation shows no such association.
|
10398103 |
1999 |
rs121913529
|
|
|
0.800 |
GeneticVariation |
UNIPROT |
|
|
|
rs121913240
|
|
|
0.710 |
GeneticVariation |
UNIPROT |
|
|
|
rs121913527
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs770248150
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|